To corroborate these findings, we used mice with patient-derived xenografts (PDXs) from triple-negative breast cancer, and found neither increase in transcripts of p16Ink4a, p21waf1 and PAI nor in β-galactosidase activity in tumours of MitoTam-treated mice (Fig. 1f, g). This evidence concerns the gene CDKN2A and triple-negative breast carcinoma.